Pharmacokinetics and pharmacodynamics of newer macrolides

Pediatric Infectious Disease Journal

Volumn 16, Issue 4, 1997, Pages 438-443

  Nightingale, Charles H ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Azithromycin; clarithromycin; concentration independent; concentration dependent; erythromycin

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; MACROLIDE;

ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; BACTERIAL INFECTION; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONFERENCE PAPER; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; HAEMOPHILUS INFLUENZAE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; CLARITHROMYCIN; EAR, MIDDLE; HAEMOPHILUS INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; MICROBIAL SENSITIVITY TESTS; STREPTOCOCCAL INFECTIONS; TISSUE DISTRIBUTION;

EID: 0030952990     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199704000-00027     Document Type: Conference Paper

References (29)

1. Quintiliani R, Nightingale CH, Freeman CD. Pharmacokinetic and pharmacodynamic considerations in antibiotic selection, with particular attention to oral cephalosporins. Infect Dis Clin Pract 1994;3:1-7.
2. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25(Suppl A):73-82.
3. Chu SY, Deaton R, Cavanaugh J. Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrob Agents Chemother 1992;36:1147-50.
4. Nahata MC, Koranyi KI, Luke DR, Foulds G. Pharmacokinetics of azithromycin in pediatric patients with acute otitis media. Antimicrob Agents Chemother 1995;39:1875-7.
5. Nahata MC, Koranyi KI, Gadgil SD, et al. Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension. Antimicrob Agents Chemother 1993;37:314-6.
6. Gan VN, Chu SY, Kusmiesz HT, Craft JC. Pharmacokinetics of a clarithromycin suspension in infants and children. Antimicrob Agents Chemother 1992;36:2478-80.
7. Data on file. Pfizer Inc, New York, NY.
8. Foulds G, Luke DR, Teng R, Willairze SA, Friedman H, Curotolo WJ. The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension. J Antimicrob Chemother 1996;37(Suppl C):37-44.
9. Physicians Desk Reference®. 50th ed. Montvale, NJ: Medical Economics Co., 1996.
10. Schentag JJ, Ballow CH. Tissue-directed pharmacokinetics. Am J Med 1991;91(Suppl 3A):5S-11S.
11. Ferrero JL, Bopp BA, Marsh KC, et al. Metabolism and disposition of clarithromycin in man. Drug Metab Dispos 1990;18:441-6.
12. Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992;23:106-31.
13. Harris S, Hilligoss DM, Colangelo PM, Eller M, Okerholm R. Azithromycin and terfenadine: lack of drug interaction. Clin Pharmacol Ther 1995;58:310-5.
14. Rapeport WG, Dewland PM, Muirhead DC, Forster PL. Lack of an interaction between azithromycin and carbamazepine. Br J Clin Pharmacol 1992;33:551P.
15. Gardner MJ, Coates PE, Hilligoss DM, Henry EB. The effect of azithromycin on the pharmacokinetics of single and multiple doses of theophylline. Drug Invest (in press).
16. Chave JP, Munafo A, Chatton JY, Dayer P, Glauser MP, Biollaz J. Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. Antimicrob Agents Chemother 1992;36:1013-8.
17. Nahata M. Drug interactions with azithromycin and the macrolides: an overview. J Antimicrob Chemother 1996;37: 133-42.
18. Honig PK, Wortham DC, Zamani K, Cantilena LR. Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Invest 1994;7:148-56.
19. Peters DH, Clissold SP. Clarithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992;44:117-65.
20. Patel KB, Xuan D, Tessier PR, Russomanno JH, Quintiliani R, Nightingale CH. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother 1996;40:2375-9.
21. Pukander J, Rautianen M. Penetration of azithromycin into middle ear effusions in acute and secretory otitis media in children. J Antimicrob Chemother 1996;37(Suppl C):53-61.
22. Guay DRP, Craft JC. Overview of the pharmacology of clarithromycin suspension in children and a comparison with that in adults. Pediatr Infect Dis J 1993;12:S106-11.
23. Carr RA, Gustavson LE, Palmer RN, et al. Penetration of clarithromycin into middle ear fluid after multiple doses of clarithromycin suspension to pediatric patients with acute otitis media [Abstract 4.04]. Poster presentation at the Third International Conference on the Macrolides, Azalides and Streptogramins, Lisbon, Portugal, January 24 to 26, 1996.
24. Hardy DJ, Hensey DM, Beyer JM, Vojtko C, McDonald EJ, Fernandes PB. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob Agents Chemother 1988;32:1710-9.
25. Nahata MC. Pharmacokinetics of azithromycin in pediatric patients: comparison with other agents used for treating otitis media and streptococcal pharyngitis. Pediatr Infect Dis J 1995;14:S39-44.
26. Barry AL, Pfaller MA, Fuchs PC, Packer RR. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U. S. medical centers in 1992 and 1993. Antimicrob Agents Chemother 1994;38:2419-25.
27. Hardy DJ. Extent and spectrum of the antimicrobial activity of clarithromycin. Pediatr Infect Dis J 1993;12(Suppl):S99-105.
28. Craig W, Rikardsdottir S, Watanabe Y. In vivo and in vitro postantibiotic effects (PAEs) of azithromycin [Abstract 45]. In: Program and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1992:118.
29. Baldwin DR, Wise R, Andrews JM, Ashby JP, Honeybourne D. Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J 1990;3:886-90.